Chemotherapy

Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.

What is Chemotherapy?

Chemotherapy literally refers to the treatment of certain diseases using specific chemicals that are destructive to malignant cells or to the causative agent of a disease such as a bacteria or virus. Therefore, the treatment can be broadly divided into two categories - cancer chemotherapy and antimicrobial chemotherapy.

Chemotherapy Types

How Chemotherapy Affects Daily Living

Chemotherapy Treatment Schemes

History of Chemotherapy

What is 'Chemo Brain'?

Does Scalp Cooling Prevent Hair Loss During Chemotherapy?

Chemotherapy Principles

Latest Chemotherapy News and Research

Recurrent brain tumors undergo unique genetic changes after treatment

When patients are diagnosed with certain brain tumors, one of the biggest unanswered questions is what happens when the cancer returns.

14 Oct 2026

CSHL researchers find way to make immunotherapy effective against colorectal cancer

Colorectal cancer has become the leading cause of cancer-related death for people under 50. Its most common forms generally aren't treatable, either through conventional means like chemotherapy or newer immunotherapy drugs.

14 Oct 2026

Long non-coding RNAs offer new pathways to overcome cancer treatment resistance

Scientists are highlighting long non-coding RNAs (lncRNAs) as promising targets in the effort to overcome one of cancer treatment's most persistent challenges: therapeutic resistance.

12 Oct 2026

Targeting mitochondrial vulnerabilities could help treat triple-negative breast cancer

A deeper understanding of mitochondrial function could create new opportunities for treating triple-negative breast cancer (TNBC), one of the most aggressive and difficult-to-treat forms of breast cancer.

12 Oct 2026

Amphista Therapeutics announces first patient dosed in AMX-883 Phase 1 clinical trial for acute myeloid leukemia

Amphista Therapeutics Limited ('Amphista'), a leader in the discovery and development of non-cereblon / VHL targeted protein degradation (TPD) medicines, today announced dosing of the first patient in a Phase 1 trial for its lead candidate, AMX-883. Initiated following authorization from the U.S. Food and Drug Administration in June 2026, the BRAMLIE trial will investigate the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with AML and high-risk MDS.

From Amphista Therapeutics 12 Oct 2026

FDA approves atezolizumab combination for stage III colon cancer with deficient DNA mismatch repair

The Alliance for Clinical Trials in Oncology (Alliance) today announced that the U.S. Food and Drug Administration has approved the immunotherapy drug atezolizumab (Tecentriq) in combination with fluoropyrimidine and oxaliplatin chemotherapy, for the adjuvant treatment of patients with stage III colon cancer with deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR).

9 Oct 2026

New research unveils role of innate immune system in pancreatic cancer

Researchers from Adelaide University have demonstrated that blocking a specific immune system gene can reduce pancreatic cancer tumor formation.

9 Oct 2026

What young cancer survivors revealed about stress, exercise and friendship

Adolescent and young adult cancer survivors use exercise and social support to cope with stress, revealing insights for effective mental health interventions.

9 Oct 2026

SPRED2 coordinates three signaling pathways to suppress liver cancer stemness

Liver cancer is the fifth most commonly diagnosed cancer and the second leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) accounts for 70-85% of primary liver cancers, and its five-year recurrence rate can reach 70-80%.

8 Oct 2026

Rare dendritic cells may promote immune tolerance in metastatic cancer

This study was co-led by Steven Blum, MD. Gary Reynolds, MD, PhD, Samuel Klempner, MD, and Alexandra-Chloé Villani, PhD, jointly supervised the work at the Krantz Family Center for Cancer Research within the Mass General Brigham Cancer Institute and the Mass General Brigham Center for Immunology & Inflammatory Diseases (CIID).

8 Oct 2026

Disrupted circadian rhythms may influence tumor immunity and cancer spread

Epidemiological studies link light at night (LAN), shift work, chronic jet lag (CJL), and core clock gene mutations to higher cancer risk and aggressive spread, especially in breast and colorectal cancer.

8 Oct 2026

A New Approach to Preventing Bladder Cancer Recurrence

Innovative techniques using electrical energy to treat bladder cancer may lower recurrence rates and minimize the need for radical surgical interventions.

8 Oct 2026

UK doctors transplant frozen testicular tissue to restore fertility

Doctors in Edinburgh have performed a pioneering procedure to transplant a young man's testicular tissue that was frozen before he underwent chemotherapy, in a potential breakthrough for male fertility preservation.

8 Oct 2026

Nerve-stimulation device enters human trials for cancer-related cachexia

The Terasaki Institute for Biomedical Innovation announced today that OnVagus, a medical device company incubating at the Institute, has received institutional and regulatory approval to begin the first human trial of its noninvasive nerve-stimulation device for patients experiencing cancer-related wasting.

7 Oct 2026

Study reveals link between mtDNA copy number and cancer severity

Mitochondria are small organelles within cells that play a central role in vital cellular processes, especially energy production.

7 Oct 2026

UK first as frozen testicular tissue transplanted to help restore fertility

7 Oct 2026

Study identifies RGS4 protein as potential target for chronic pain

Chronic pain can continue long after an initial injury. When a nerve outside the brain and spinal cord (a peripheral nerve) is damaged and does not heal properly, it keeps sending constant pain signals.

6 Oct 2026

Global scientific collaboration brings hope to lobular breast cancer patients

Every October, Breast Cancer Awareness Month brings people around the world together under the pink ribbon to raise awareness, encourage early detection, support patients and fund research.

6 Oct 2026

Phase III trial tests MRD-guided treatment for patients with ER-positive/HER2-negative breast cancer

Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer.

5 Oct 2026